Inogen (INGN) Set to Release Earnings on Thursday

Key Points

• Inogen is expected to report Q3 2026 results after market close on November 5. Analysts forecast a loss of $0.11 per share and revenue of approximately $92.23 million.
• In the prior quarter, Inogen reported a $0.14-per-share loss, beating estimates by $0.01, while revenue of $95.08 million fell slightly short of expectations.
• The stock recently traded at $7.25 and remains financially challenged, with a negative net margin and return on equity. Analyst sentiment is mixed, with one Strong Buy and one Sell rating, producing a consensus “Moderate Buy.”

Inogen (NASDAQ:INGN - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Inogen to announce earnings of ($0.11) per share and revenue of $92.23 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical technology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. Inogen had a negative net margin of 6.94% and a negative return on equity of 13.17%. The business had revenue of $95.08 million during the quarter, compared to analysts' expectations of $95.23 million.

Inogen Stock Performance

INGN opened at $7.25 on Thursday. Inogen has a one year low of $5.05 and a one year high of $8.69. The stock has a market capitalization of $192.40 million, a PE ratio of -8.06 and a beta of 1.50. The business's 50 day moving average price is $5.78 and its 200 day moving average price is $6.21.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Inogen in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Inogen presently has a consensus rating of "Moderate Buy".

Inogen Company Profile

Inogen, Inc is a medical technology company that develops, manufactures and markets portable oxygen concentrators for people who require long-term supplemental oxygen therapy. Its devices separate oxygen from ambient air and deliver concentrated oxygen without the need for traditional compressed-gas or liquid-oxygen tanks.

The company's product portfolio has included the Inogen One portable oxygen concentrator line, as well as stationary and related oxygen therapy products. These systems are designed to support mobility and independence for patients with chronic respiratory conditions while offering features such as rechargeable batteries, portability and various oxygen-delivery settings.

Founded in 2001 and headquartered in Goleta, California, Inogen sells its products through direct-to-consumer channels, health-care providers, distributors and other commercial partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.